Premium
Dosing with ropinirole in a clinical setting
Author(s) -
Korczyn A. D.,
Thalamas C.,
Adler C. H.
Publication year - 2002
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1034/j.1600-0404.2002.01343.x
Subject(s) - medicine , dosing , ropinirole , clinical endpoint , clinical trial , anesthesia , parkinson's disease , disease , levodopa
Korczyn AD, Thalamas C, Adler CH. Dosing with ropinirole in a clinical setting. Acta Neurol Scand 2002: 106: 200–204. © Blackwell Munksgaard 2002. Objectives – To determine the optimal dose of ropinirole (ReQuip ® ) for treatment of early Parkinson's disease (PD). Materials and methods – Six‐month data were gathered from three trials of monotherapy in patients with PD. Results – Seventy‐five percent of patients who experienced a therapeutic response did so at ≤ 7.5 mg/day. Patients whose dose was increased by more than four titration levels from weeks 4–24 (mean total increase 14.8 mg/day) tended to show greater improvements than those whose dose increase was smaller (mean increase 3.4 mg/day) (17.4% vs 10.8%, respectively). Mean doses continued to increase throughout the 3‐ and 5‐year trials (3‐year trial at endpoint, 10.4 mg/day; 5‐year trial at 3 years and at endpoint, 14.1 and 14.9 mg/day, respectively). Conclusion – Although a therapeutic response may be expected at ≤ 7.5 mg/day, these data suggest a benefit for continued dose titration in most patients with early PD. For some patients, the maximum recommended dose (24 mg/day) may be necessary.